**Title: Risk of diabetes and cardiovascular diseases in women with pregnancies complicated by vaginal bleeding: Danish population-based cohort study**

Elena Dudukina,[1] Erzsébet Horváth-Puhó,[1] Henrik Toft Sørensen,[1] Vera Ehrenstein[1]

[1]Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

**Corresponding author:**

Elena Dudukina

Olof Palmes Alle 43-45

8200

Aarhus N

Email: e.dudukina@clin.au.dk

Word count: 3163

Abstract word count: 399

Dudukina E, Horváth-Puhó E, Sørensen HT, Ehrenstein V. Diabetes and cardiovascular diseases in women with pregnancies complicated by vaginal bleeding: Danish population-based cohort study

**ABSTRACT**

**Objective**: To investigate an association between childbirths affected by vaginal bleeding within 20 gestational weeks and women's subsequent risks of diabetes and cardiovascular diseases.

**Design**: Cohort study in Denmark, 1979-2018.

**Setting**: Danish nationwide registries.

**Participants**: Between 1979 and 2017, we identified 3,085,955 pregnancies among 1,329,331 women. Of these pregnancies, 69,230 ended in a childbirth affected by vaginal bleeding (VB) within 20 gestational weeks; 2,180,855 ended in a VB-unaffected childbirth; 578,355 ended in a termination, and 258,430 ended in a miscarriage.

**Main outcome measures**: The outcomes were diabetes types 1 and 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke, coronary artery bypass grafting, and percutaneous coronary intervention. We computed the incidence rates per 10,000 person-years and cumulative incidences of cardiovascular outcomes at up to 40 years of follow-up. Hazard ratios (HRs) with 95% confidence intervals adjusted for age, calendar year, reproductive history, baseline comorbidities, and socioeconomic factors were computed using conventionally and inverse probability of treatment weighted Cox proportional hazards regression.

**Results**: At the end of the follow-up, among women with VB-affected vs VB-unaffected childbirths, the cumulative risks of the outcome events were 4.5% vs 3.5% for diabetes type

1; 13.8% vs 11.1% for diabetes type 2; 25.1% vs 21.4% for hypertension; 10.6% vs 8.2% for ischaemic heart disease, including 2.9% vs 2.6% for myocardial infarction; 5.3% vs 4.4% for atrial fibrillation or flutter; 2.3% vs 2.0% for heart failure; 5.1% vs 4.0% for ischaemic stroke; 1.8% vs 1.4% for haemorrhagic stroke; 0.5% vs 0.4% for coronary artery bypass graft; and 2.4% vs 1.9% for percutaneous coronary intervention. Adjusted HRs were 1.2 to 1.3-fold increased for diabetes types 1 and 2, hypertension, ischaemic heart disease, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke as well as a coronary artery bypass grafting. Following women's first pregnancies and in sensitivity analyses, the HRs remained increased. For comparisons of VB-affected childbirths with terminations, HRs were up to 1.3-fold increased for diabetes and 1.1-fold increased for hypertension, ischaemic heart disease, atrial fibrillation or flutter, and haemorrhagic stroke. HRs were unity when we compared having a VB-affected childbirth with having a miscarriage.

**Conclusions**: Women's risks of diabetes types 1 and 2 and multiple cardiovascular outcomes were increased on the relative scale following childbirths affected by VB within 20 gestational weeks when compared with VB-unaffected childbirths and terminations, but not when compared with miscarriages.

**WHAT IS ALREADY KNOWN ON THIS TOPIC**

- Vaginal bleeding is a common complication affecting up to 30% of clinically detected pregnancies.
- Although an association between miscarriages and greater risk of cardiovascular events is known, the risk of cardiovascular outcomes following a childbirth complicated by vaginal bleeding not ending in a miscarriage is not well investigated.

**WHAT THIS STUDY ADDS**

- This nationwide registry-based cohort study with up to 40 years of follow-up showed that compared with having a childbirth without vaginal bleeding, having a childbirth with vaginal bleeding within 20 gestational weeks was associated with woman's increased risk of diabetes types 1 and 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, coronary artery bypass grafting, ischaemic and haemorrhagic stroke.
- The cardiovascular risks were increased following women's first pregnancies and when additionally adjusted for smoking and body-mass index.
- The long-term cardiovascular risk profile of women with vaginal bleeding-affected childbirths was similar to that of women with miscarriages.

## INTRODUCTION

Women's reproductive health is a predictor of cardiovascular morbidity.[1] Women whose first pregnancy ended in a miscarriage have a 20% greater relative risk of hypertension and type 2 diabetes.[2,3] Furthermore, history of a miscarriage is associated with a 20% increased risk of cardiovascular morbidity in women,[4] history of more than one miscarriage is associated with a 10-20% increased risk of stroke, thromboembolism, ischaemic heart disease, and 30% increased risk of cardiovascular diseases.[1,4,5]

Vaginal bleeding (VB) is a pregnancy complication affecting up to 30%[6–8] of clinically recognised pregnancies and is associated with miscarriage.[9] Approximately a third of pregnancies complicated by VB ends in pregnancy loss.[10] At the same time, there are little data on whether VB in pregnancy not ending in a miscarriage is associated with subsequent cardiovascular morbidity. A previous Danish study[11] reported a 25-60% higher risk of multiple cardiovascular outcomes in women following a pregnancy with VB; however, analyses did not control for pre-pregnancy conditions and socioeconomic factors. Comparisons of VB-affected childbirths with alternatively ending pregnancies (terminations or miscarriages) are missing in the literature.

The aim of this study was to investigate the association of VB within 20 gestational weeks of a pregnancy ending in a childbirth with the woman's subsequent risks of diabetes, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke, coronary artery bypass grafting (CABG), and percutaneous coronary intervention (PCI).

## METHODS

### Setting and design

We conducted a registry-based cohort study using prospectively and routinely recorded data of the Danish registries,[12,13] which are collected in the context of Denmark's universal tax-supported healthcare. Data from all registries are linkable via a unique personal identifier stored in the Civil Registration System (CRS).[12] It captures the civil and vital status of all residents, country of origin, and immigration and emigration dates. Data on all deliveries are stored in the Medical Birth Registry (MBR) available from 1973.[14] Smoking and body mass index (BMI) in pregnancy became available in the MBR starting in 1991 and 2004, respectively. Hospital encounters and procedures are captured by the Danish National Patient Registry (DNPR).[15] It stores data on medical procedures, inpatient hospital encounters since 1977 and also on outpatient specialist clinic visits and emergency room visits starting in 1995.[15] The diagnoses recorded in the DNPR are coded according to the international classification of diseases, 8$^{th}$ revision (ICD-18) in 1977-1993 and 10$^{th}$ revision (ICD-10) from 1994 onwards, while procedures are coded using the Danish Classification of Surgical Procedures and Therapies before 1996 and Nordic Medico-Statistical Committee Classification of Surgical Procedures afterwards.[15] The psychiatric admissions and outpatient specialist clinic encounters are available in this study starting from 1995 from the Psychiatric Central Research Register.[16] Nationwide data on medication dispensings are available starting in 1995 from the Danish National Prescription Registry[17]. This registry captures the Anatomical Therapeutic Classification code of the prescribed medication, and the date prescription was redeemed.[17] Data on education,[18]

employment[19] and income[20] are available from 1980, measured yearly and stored at Statistics Denmark.[21]

**The cohort of pregnancies affected by vaginal bleeding ending in a childbirth**

From the MBR,[14] we assembled the cohort of all pregnancies ending in a live- or stillbirth at the gestational age of at least 28 full weeks before 2004 and 22 full weeks thereafter. Each delivery of multiple pregnancies was counted as one childbirth. Among pregnancies ending in a childbirth, we identified those affected by VB within the first 20 gestational weeks using the DNPR. The index date for the affected pregnancies was the date of the healthcare encounter due to VB. When several VB episodes occurred within 20 gestational weeks of the same pregnancy, the first episode served as the qualifying event (Figure 1).

**The comparison cohorts of pregnancies unaffected by vaginal bleeding ending in a childbirth, pregnancies ending in a termination or miscarriage**

The pregnancies ending in a childbirth found in the MBR and without a record of VB within 20 gestational weeks in the DNPR formed a comparison cohort of VB-unaffected childbirths and their index date was the date of delivery.

We ascertained pregnancies ending in a miscarriage or termination using the primary and secondary diagnoses at any hospital visit. When a miscarriage or pregnancy termination encounter had several dates associated with it (hospital admission, procedure, hospital discharge), we selected the earliest of them as the index date (Table S1). A woman with a pregnancy termination encounter characterised by the same diagnostic or procedure code as her previous encounter could re-enter the population of terminations after 180 days. We assumed that the hospital encounter with the same pregnancy-related diagnostic or

procedure code within 180 days since an earlier such encounter may be related to the complications of the previous event. We applied the same algorithm for miscarriages.

We excluded pregnancies of women with history of cardiovascular conditions and diabetes types 1 and 2 (N=78,456) before the index date; childbirths with missing gestational age (N=71,450); and pregnancies with different reproductive events (delivery, miscarriage, termination, or VB) recorded on the same date (N=6,749). Finally, we excluded pregnancies of women whose personal identifier could not be linked with the CRS data, pregnancies with potentially wrongly recorded women's age (<10 years), and pregnancies recorded after the woman emigrated from Denmark (N=14,094) (Figure 1). We also ascertained the subset of women having their first pregnancy. From this, we additionally excluded women with a record of pre-existing hypercholesterolaemia and hyperlipidaemia in the DNPR.

**Diabetes types 1 and 2 and cardiovascular outcomes**

The outcomes were incident diabetes type 1 and type 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke, CABG, and PCI. We used all available primary and secondary diagnoses recorded in connection with inpatient, outpatient specialist clinic, and emergency room encounters from the DNPR (1979-2018). Diabetes and hypertension outcomes were defined based on the earliest of the hospital-based diagnosis or medication dispensing. For CABG and PCI, the outcomes were defined using procedure codes from the DNPR (Table S1).

**Covariables**

Potential confounding factors were selected using the directed acyclic graph presenting the evidence on the associations or lack of thereof between the measured and unmeasured

variables in this study (Figure S1). These were women's age, calendar year of pregnancy end, parity (nulli- or primiparous vs multiparous) as the number of delivered live- and stillborn infants, civil status, employment status, highest attained education, annual women's income in quartiles; reproductive history (VB diagnosis irrespective of a later delivery record, history of VB within 20 gestational weeks of pregnancy ending in a childbirth, history of a termination or miscarriage), obesity, chronic obstructive pulmonary disease (COPD), chronic kidney and liver diseases, cancer, and psychiatric conditions before the index date. As proxies for the underlying health, we also ascertained the medication use history before the index date of antipsychotics, mood disorders medication, antiepileptics, non-steroid anti-inflammatory drugs [NSAIDs], steroids for systemic use, anti-infectives, and at least one prescription of a beta-blocker, RAS-acting agent, or a diuretic.

**Statistical analysis**

We followed each pregnancy from its index date until the earliest of each of the outcomes, emigration, death, or end of data on 31 December 2018. We constructed the cumulative incidence curves for the outcomes while treating death and emigration as competing risks and computed incidence rates (IR) of the outcomes per 10,000 person-years (PY) among women with VB-affected and VB-unaffected childbirths, terminations, and miscarriages.[22] We used Cox proportional hazards regression to compute the hazards ratios (HRs) for the outcomes of interest with the corresponding 95% confidence intervals (CIs). Different outcomes did not censor one another. To account for different pregnancies in the same woman, we computed the 95% CIs using a robust standard error estimation with *survival* R package.[23–25]

Contrasting women with VB-affected childbirths with each of the comparisons, we computed conventionally adjusted HRs using multivariable Cox regression models and stabilized inverse probability of treatment weighted (IPTW) models for an average treatment effect (ATE), where treatment refers to VB exposure.[26,27] We also computed HRs for average treatment effect in the treated (ATT) using ATT weights[28,29]. We truncated IPTW and ATT weights at the 1$^{st}$ and 99$^{th}$ percentiles.[27] Finally, we repeated all analyses restricting to women's first pregnancies (Table S2). We evaluated the proportionality of hazards assumptions by using log-minus-log plots and found no deviation of the curves from being parallel for all Cox proportional hazards regression models.

We performed several sensitivity analyses. First, we additionally adjusted for smoking among women with childbirths in 1992-2017. Second, we restricted analyses to women with pregnancies in the ICD-10 era (1994-2017) (Table S3). Third, we further adjusted for smoking and pre-pregnancy BMI in the analyses of women with childbirths in 2004-2017 (Table S4). Fourth, we restricted to women's last recorded pregnancies at the age of 40+ years and additionally adjusted for preeclampsia-eclampsia and placental pregnancy complications history (Table S5).

For all analyses we used RStudio[30] and R[31] versions 3.6.0-4.1.0 including the following packages and their dependencies: tidyverse,[32] ggplot2,[33] survival,[24] cmprsk,[34] epiR[35]. All presented counts are masked as mandated by Statistics Denmark.[21]

No patient informed consent or ethical approval is required for registry-based research according to Danish legislation. The study was reported to the Danish Data Protection Agency[36] through registration at Aarhus University (record number: AU-2016-051-000001, sequential number 605).

## RESULTS

### Descriptive characteristics

Between 1979 and 2017, we identified 3,085,955 pregnancies among 1,329,331 women. Of these, 69,230 (2.2%) ended in VB-affected childbirths; 2,179,940 (70.6%) ended in VB-unaffected childbirths; 578,355 (18.8%) ended in a termination, and 258,430 (8.4%) pregnancies ended in a miscarriage. VB-affected and VB-unaffected childbirths had a similar distribution of women's age at delivery, parity, civil status, employment, highest attained education, income, history of obesity, COPD, chronic kidney and liver disease, alcohol abuse, and medication utilization (Table 1). VB-affected childbirths were more likely than VB-unaffected childbirths to be of women with a prior miscarriage (26% vs 12%) and a prior psychiatric condition (7.9% vs 6.7%). History of VB in pregnancy was most prevalent in VB-affected childbirths (Table 1). Pregnancies ending in a termination were more likely to be of women of younger age, nulliparous, not married, in the first income quartile and with a prior psychiatric condition (Table 1).

### Risks and rates of diabetes and cardiovascular outcomes

During the follow-up of up to 40 years, following VB-affected childbirth there were 1,265 events of diabetes type 1 (IR=8.3, 95% CI: 7.8-8.8 per 10,000 PY); 3,870 events of diabetes type 2 (25.7, 95% CI: 24.9-26.5); 6,485 events of hypertension (43.7, 95% CI: 42.6-44.8); 2,985 events of ischaemic heart disease (19.7, 95% CI: 19.0-20.5), including 745 events of myocardial infarction (4.9, 95% CI: 4.5-5.2); 1,015 events of atrial fibrillation or flutter (6.6, 95% CI: 6.2-7.1); 505 events of heart failure (3.3, 95% CI: 3.0-3.6); 1,295 ischaemic stroke

events (8.5, 95% CI: 8.0-8.9); 565 haemorrhagic stroke events (3.7, 95% CI: 3.4-4.0); as well as 80 CABG (0.5, 95% CI: 0.4-0.7) and 465 PCI events (2.5, 95% CI: 2.1-3.0) (Table 2).

At the end of follow-up, for women with VB-affected vs VB-unaffected childbirths, the cumulative incidences of the outcomes were: 4.5% vs 3.5% for diabetes type 1; 13.8% vs 11.1% for diabetes type 2; 25.1% vs 21.4% for hypertension; 10.6% vs 8.2% for ischaemic heart disease, including 2.9% vs 2.6% for myocardial infarction; 5.3% vs 4.4% for atrial fibrillation or flutter; 2.3% vs 2.0% for heart failure; 5.1% vs 4.0% for ischaemic stroke; 1.8% vs 1.4% for haemorrhagic stroke; 0.5% vs 0.4% for CABG; and 2.4% vs 1.9% for PCI (Figure S2, Table S6). The cumulative incidences of the outcomes at 5, 10, 20, and 30 years of follow-up are reported in Table S6.

**Hazard ratios for diabetes and the cardiovascular outcomes**

When contrasting VB-affected vs VB-unaffected childbirths, there was a greater risk of diabetes type 1 (conventional adjusted HR: 1.22, 95% CI: 1.15-1.29), diabetes type 2 (HR: 1.21, 1.17-1.25), hypertension (HR: 1.15, 1.12-1.18), ischaemic heart disease (HR: 1.31, 1.26-1.36) and specifically myocardial infarction (HR: 1.17, 1.09-1.26), atrial fibrillation or flutter (HR: 1.19, 1.12-1.27), heart failure (HR: 1.21, 1.11-1.33), ischaemic (HR: 1.26, 1.19-1.33) and haemorrhagic stroke (HR: 1.27, 1.17-1.39). The risk was also increased for CABG (HR: 1.24, 0.99-1.55) but not for PCI (HR: 1.05, 0.96-1.16). The elevated risks persisted in the analyses restricted to women's first pregnancies, and HR for PCI was 1.18, 0.98-1.43 (Table 3). The HRs for the ATT effect and conventional HRs were less pronounced than HR for ATE effect adjusted with IPTW.

When comparing VB-affected childbirths with terminations, the risks were increased for diabetes type 1 (conventional adjusted HR: 1.28, 95% CI: 1.20-1.37), diabetes type 2 (HR:

1.34, 1.26-1.42), hypertension (HR: 1.11, 1.08-1.14), ischaemic heart disease (HR: 1.11, 1.06-1.16), atrial fibrillation or flutter (HR: 1.10, 1.02-1.18), haemorrhagic stroke (HR: 1.10, 1.00-1.21), but not for myocardial infarction (HR: 1.00, 0.92-1.09), heart failure (HR: 1.02, 0.92-1.12), ischaemic stroke (HR: 1.04, 0.98-1.11), CABG (HR: 1.07, 0.84-1.37) and PCI (HR: 0.96, 0.86-1.06). Following first pregnancies, the associations remained unity for heart failure and atrial fibrillation or flutter and were 1.2 to 1.3-fold increased for diabetes types 1 and 2, hypertension, ischaemic heart disease, ischaemic and haemorrhagic stroke (Table 3).

When contrasted with having a pregnancy ending in a miscarriage, having a VB-affected childbirth was not associated with diabetes type 1 or type 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic, and haemorrhagic stroke in women (Table 3). Furthermore, no association was found for CABG and PCI (Table 3). The findings were similar when we followed women's first pregnancies (Table 3).

The results remained unchanged after additional adjustment for women's smoking and BMI in pregnancy in the comparisons of VB-affected with VB-unaffected childbirths and when restricted to women with pregnancies recorded in 1994-2017. In analyses of women's last childbirths at the age of 40+ years and additionally adjusted for the history of preeclampsia-eclampsia and placental complications, the associations remained for diabetes type 1, hypertension, ischaemic heart disease, and CABG (Table S7-10).

## DISCUSSION

### Principal findings

In this population-based cohort study at the end of up to 40 years of follow-up, the hazards of diabetes types 1 and 2 as well as of cardiovascular outcomes were 1.2 to 1.3-fold increased for women with VB-affected vs VB-unaffected childbirths. The associations persisted in the analyses restricted to first pregnancies and in the sensitivity analyses additionally controlling for smoking and body mass index. We found that the hazards of diabetes types 1 and 2, hypertension, ischaemic heart disease, atrial fibrillation or flutter, and haemorrhagic stroke were 1.1 to 1.3-fold greater in women following VB-affected childbirths vs terminations. No increased risks of the outcomes of interest were observed in the comparisons of women having VB-affected childbirths vs miscarriages. The findings suggested that having a pregnancy complicated by VB despite a childbirth was associated with increased cardiovascular risk.

### Comparison with other studies

An earlier Danish study showed a greater risk of cardiovascular morbidity following pregnancies with VB.[11] In contrast to our study, it used a different definition of VB restricting the exposure window to 12 gestational weeks, the observation ended in 2007, investigated outcomes included overall stroke and overall diabetes types 1 and 2, no comparisons with pregnancies ending in a termination or miscarriage were carried out. Moreover, in contrast to our study, analyses in the previous study were not adjusted for socioeconomic factors and pre-pregnancy morbidity but were adjusted for post-exposure factors such as preterm delivery, prelabour rupture of membranes, foetal growth

restriction, placental abruption and stillbirth. These could be both mediators and colliders on the pathway from VB in pregnancy to subsequent cardiovascular morbidity in women. Adjusting for post-exposure factors that are colliders could result in inflated associations (Figure S3).[37]

Underlying biological mechanisms of VB in pregnancy are not fully known. Markers of systemic inflammation are associated with both miscarriages[38,39] and VB in pregnancy[40–43] and were found to contribute to the development of cardiovascular disease and diabetes type 2.[44] Dislipidemia, insulin resistance, and obesity are risk factors of diabetes type 2 and hypertension, which result in endothelial dysfunction and microvascular inflammation and damage further leading to cardiovascular diseases.[45] The existence of common metabolic and pro-inflammatory pathways via cytokines (IL-1β, IL-6, TNF-α) for VB, miscarriage and vascular pathology could contribute to the explanation of the findings of this study showing an elevated cardiovascular risk in women with a VB-affected childbirth vs women having a VB-unaffected childbirth or a termination but not a miscarriage.

**Strengths and limitations of the study**

One Danish study showed that most women with VB in pregnancy received ultrasound[6] required to establish foetal heart activity at bleeding presentation and exclude miscarriage and ectopic pregnancy. The number of false-positive VBs due to threatened abortion in this study is likely small. At the same time, we were unable to capture episodes of VB not resulting in a hospital-based contact and, therefore, could miss a considerable proportion of affected pregnancies.[6] We would also miss a proportion of very early miscarriages. Non-differential misclassification of pregnancies' status would result in diluted associations.

The diagnoses for miscarriage (spontaneous abortions) in the DNPR were previously validated and showed PPV of 97%[46]. The diagnostic and procedure codes for medical and surgical abortions (pregnancy terminations) were not validated in the DNPR, however, the provoked abortion diagnosis in the Register of Legally Induced Abortions had PPV of 94% and procedure codes, in general, have high validity in the DNPR.[15]

The outcome diagnoses were validated with high PPV for diabetes (82-96%),[47] hypertension (92%), PCI (98%),[48] and slightly lower PPV for heart failure (76%),[48] and haemorrhagic stroke (71-80%)[49,50], leading to relatively few false-positive outcomes. The PPV for ischaemic stroke was 71-85%[49,50]; however, since the definition of ischaemic stroke in this study included undefined stroke diagnoses, a larger proportion of false positives may be present. Non-differential misclassification of the outcome is expected to dilute the associations toward or beyond the null value.

Owing to the universal healthcare coverage, routine data collection and nearly complete follow-up, the selection bias due to lost-to-follow-up is not expected. The residual confounding by obesity is likely since we had data only on hospital-based diagnoses. Although additional adjustment of analyses for smoking and BMI did not meaningfully shift the HR estimates, the concern of unmeasured and residual confounding remains. An unmeasured confounder associated with VB and with cardiovascular outcomes with the hazard ratio of 1.7-1.8 beyond measured covariables could fully explain away the observed associations according to E-value analysis.[51]

This study investigated the total effect of VB during pregnancy on the long-term risk of diabetes type 1 and type 2 and cardiovascular outcomes in women. Although we did not investigate the specific pathways of cardiovascular morbidity in women following a VB-

affected childbirth, associations with diabetes type 2 and hypertension suggest that metabolic syndrome may be one of them. We cannot exclude that part of the observed association between VB and the outcomes may be mediated via miscarriages of women's subsequent pregnancies.

**CONCLUSION**

Childbirths affected by VB within 20 gestational weeks were associated with an increased relative risk of diabetes types 1 and 2 and multiple cardiovascular outcomes in women when compared with VB-unaffected childbirths and terminations, but not miscarriages.

**Contributors**: ED, EHP, HTS, VE designed the study. HTS facilitated the data application process. ED designed the statistical analysis plan. ED conducted the analyses, EHP provided expertise and supervision of the data analysis. All authors participated in the discussion of the results and their critical interpretation. ED drafted the manuscript, organised the writing, and produced a graphical presentation of the results. HTS provided clinical expertise. All authors equally participated in the critical revision of the manuscript and approved its final version. HTS is the guarantor.

**Funding**: Department of Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from regulators and pharmaceutical companies, given as research grants to and administered by Aarhus University. None of these projects is related to the current study.

**Competing interests:** All authors report no competing interest

**Ethics approval:** not required for registry-based research in Denmark.

**Data sharing:** data is not available for sharing to protect the identity of participants according to Danish legislation.

**Patient and public involvement:** patients or the public were not involved in the design, or conduct, or reporting, or dissemination of this research.

## REFERENCES


1 Okoth K, Chandan JS, Marshall T, *et al.* Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. *BMJ* 2020;**371**:m3502. doi:10.1136/bmj.m3502

2 Horn J, Tanz LJ, Stuart JJ, *et al.* Early or late pregnancy loss and development of clinical cardiovascular disease risk factors: a prospective cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology* 2019;**126**:33–42. doi:10.1111/1471-0528.15452

3 Harvey RE, Coffman KE, Miller VM. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. *Womens Health (Lond Engl)* 2015;**11**:239–57. doi:10.2217/whe.14.64

4 Quenby S, Gallos ID, Dhillon-Smith RK, *et al.* Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. *The Lancet* 2021;**397**:1658–67. doi:10.1016/S0140-6736(21)00682-6

5 Oliver-Williams CT, Heydon EE, Smith GC, *et al.* Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis. *Heart* 2013;**99**:1636–44. doi:10.1136/heartjnl-2012-303237

6 Axelsen SM, Henriksen TB, Hedegaard M, *et al.* Characteristics of vaginal bleeding during pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1995;**63**:131–4. doi:10.1016/0301-2115(95)02236-8

7 Smits LJM, North RA, Kenny LC, *et al.* Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. *Acta Obstetricia et Gynecologica Scandinavica* 2012;**91**:1331–8. doi:10.1111/j.1600-0412.2012.01496.x

8 Saraswat L, Bhattacharya S, Maheshwari A, *et al.* Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. *BJOG* 2010;**117**:245–57. doi:10.1111/j.1471-0528.2009.02427.x

9 Coomarasamy A, Harb HM, Devall AJ, *et al.* Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. *Health Technol Assess* 2020;**24**:1–70. doi:10.3310/hta24330

10 Coomarasamy A, Gallos ID, Papadopoulou A, *et al.* Sporadic miscarriage: evidence to provide effective care. *The Lancet* 2021;**397**:1668–74. doi:10.1016/S0140-6736(21)00683-8

11 Lykke JA, Langhoff-Roos J. First trimester bleeding and maternal cardiovascular morbidity. *Eur J Obstet Gynecol Reprod Biol* 2012;**164**:138–41. doi:10.1016/j.ejogrb.2012.06.003

12 Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol* 2014;**29**:541–9. doi:10.1007/s10654-014-9930-3

13 Laugesen K, Ludvigsson JF, Schmidt M, *et al.* Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries. *CLEP* 2021;**13**:533–54. doi:10.2147/CLEP.S314959

14 Bliddal M, Broe A, Pottegard A, *et al.* The Danish Medical Birth Register. *Eur J Epidemiol* 2018;**33**:27–36. doi:10.1007/s10654-018-0356-1

15 Schmidt M, Schmidt SA, Sandegaard JL, *et al.* The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;**7**:449–90. doi:10.2147/CLEP.S91125

16 Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. *Scand J Public Health* 2011;**39**:54–7. doi:10.1177/1403494810395825

17 Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, *et al.* Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol* 2017;**46**:798–798f. doi:10.1093/ije/dyw213

18 Jensen VM, Rasmussen AW. Danish Education Registers. *Scand J Public Health* 2011;**39**:91–4. doi:10.1177/1403494810394715

19 Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. *Scand J Public Health* 2011;**39**:95–8. doi:10.1177/1403494811408483

20 Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public Health* 2011;**39**:103–5. doi:10.1177/1403494811405098

21 Statistics Denmark. 2021.https://www.dst.dk/en (accessed 30 Jun 2021).

22 Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation* 2016;**133**:601–9. doi:10.1161/CIRCULATIONAHA.115.017719

23 Therneau T, Grambsch P. *Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000*. New York: : Springer 2000.

24 Therneau TM, Thomas L, Elizabeth A, *et al. survival: Survival Analysis*. 2021. https://CRAN.R-project.org/package=survival (accessed 6 Apr 2021).

25 Efron B. Nonparametric Estimates of Standard Error: The Jackknife, the Bootstrap and Other Methods. *Biometrika* 1981;**68**:589–99. doi:10.2307/2335441

26 Hernán M, Robins JM. *Causal inference*. 2021. https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/#:~:text=To%20cite%20the%20book%2C%20please,Chapman%20%26%20Hall%2FCRC.%E2%80%9D (accessed 29 Jul 2021).

27 Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol* 2008;**168**:656–64. doi:10.1093/aje/kwn164

28 Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. *Epidemiology* 2003;**14**:680–6. doi:10.1097/01.EDE.0000081989.82616.7d

29 Sturmer T, Rothman KJ, Glynn RJ. Insights into different results from different causal contrasts in the presence of effect-measure modification. *Pharmacoepidemiol Drug Saf* 2006;**15**:698–709. doi:10.1002/pds.1231

30 RStudio Team. *RStudio: Integrated Development for R*. Boston, MA: : RStudio, PBC 2020. http://www.rstudio.com/

31 R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: 2013. http://www.R-project.org/

32 Wickham H, Averick M, Bryan J, *et al.* Welcome to the Tidyverse. *Journal of Open Source Software* 2019;**4**:1686. doi:10.21105/joss.01686

33 Wickham H. *ggplot2: Elegant Graphics for Data Analysis:Elegant Graphics for Data Analysis*. Springer-Verlag New York 2016. https://ggplot2.tidyverse.org

34 Gray B. *cmprsk: Subdistribution Analysis of Competing Risks*. 2020. https://CRAN.R-project.org/package=cmprsk (accessed 31 Mar 2021).

35 Nunes MS and ES with contributions from T, Heuer C, Marshall J, *et al. epiR: Tools for the Analysis of Epidemiological Data*. 2021. https://CRAN.R-project.org/package=epiR (accessed 29 Jul 2021).

36 Datatilsynet. Datatilsynet/The Danish Data Protection Agency. Datatilsynet/The Danish Data Protection Agency. http://www.datatilsynet.dk/english (accessed 16 Sep 2020).

37 Hernandez-Diaz S, Schisterman EF, Hernan MA. The birth weight 'paradox' uncovered? *Am J Epidemiol* 2006;**164**:1115–20. doi:10.1093/aje/kwj275

38 Ahmed SK, Mahmood N, Malalla ZH, *et al.* C-reactive protein gene variants associated with recurrent pregnancy loss independent of CRP serum levels: A case-control study. *Gene* 2015;**569**:136–40. doi:10.1016/j.gene.2015.05.052

39 Calleja-Agius J, Jauniaux E, Pizzey AR, *et al.* Investigation of systemic inflammatory response in first trimester pregnancy failure. *Human Reproduction* 2012;**27**:349–57. doi:10.1093/humrep/der402

40 Calleja-Agius J, Schembri-Wismayer P, Calleja N, *et al.* Obstetric outcome and cytokine levels in threatened miscarriage. *Gynecol Endocrinol* 2011;**27**:121–7. doi:10.3109/09513590.2010.487614

41 Calleja-Agius J, Muttukrishna S, Pizzey AR, *et al.* Pro- and antiinflammatory cytokines in threatened miscarriages. *American Journal of Obstetrics and Gynecology* 2011;**205**:83.e8-16. doi:10.1016/j.ajog.2011.02.051

42 Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, *et al.* Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. *Clin Rev Allergy Immunol* 2017;**53**:40–53. doi:10.1007/s12016-016-8596-x

43 Gücer F, Balkanli-Kaplan P, Yüksel M, *et al.* Maternal serum levels of tumor necrosis factor-α and interleukin-2 receptor in threatened abortion: a comparison with normal and pathologic pregnancies. *Fertility and Sterility* 2001;**76**:707–11. doi:10.1016/S0015-0282(01)02002-7

44 Willerson JT, Ridker PM. Inflammation as a Cardiovascular Risk Factor. *Circulation* 2004;**109**:II–2. doi:10.1161/01.CIR.0000129535.04194.38

45 Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol* 2018;**34**:575–84. doi:10.1016/j.cjca.2017.12.005

46 Lohse SR, Farkas DK, Lohse N, *et al.* Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. *Clin Epidemiol* 2010;**2**:247–50. doi:10.2147/CLEP.S13815

47 Thygesen SK, Christiansen CF, Christensen S, *et al.* The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. *BMC Med Res Methodol* 2011;**11**:83. doi:10.1186/1471-2288-11-83

48 Sundbøll J, Adelborg K, Munch T, *et al.* Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. *BMJ Open* 2016;**6**:e012832. doi:10.1136/bmjopen-2016-012832

49 Lühdorf P, Overvad K, Schmidt EB, *et al.* Predictive value of stroke discharge diagnoses in the Danish National Patient Register. *Scand J Public Health* 2017;**45**:630–6. doi:10.1177/1403494817716582

50 Wildenschild C, Mehnert F, Thomsen RW, *et al.* Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients. *Clin Epidemiol* 2013;**6**:27–36. doi:10.2147/CLEP.S50449

51 Mathur MB, Ding P, Riddell CA, *et al.* Web Site and R Package for Computing E-values. *Epidemiology* 2018;**29**:e45. doi:10.1097/EDE.0000000000000864

**Figure 1. Flow graph for the cohorts ascertainment**

**Table 1. Descriptive characteristics of vaginal bleeding-affected childbirths, vaginal bleeding-unaffected pregnancies, pregnancies ending in miscarriages, and pregnancies ending in terminations, Denmark, 1979-2017**

| | | | Comparison cohorts | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Characteristic** | **VB-affected childbirths, N = 69,230 (among 65,395 women)** | | **VB-unaffected childbirths, N = 2,179,940 (among 1,172,715 women)** | | **Terminations, N = 578,355 (among 417,765 women)** | | **Miscarriages, N = 258,430 (among 219,680 women)** | |
| | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| **Age at pregnancy end, years** | | | | | | | | |
| <20 | 1,450 | 2.1 | 48,980 | 2.2 | 89,065 | 15.0 | 10,265 | 4.0 |
| 20-24 | 12,325 | 18.0 | 374,385 | 17.0 | 139,135 | 24.0 | 44,355 | 17.0 |
| 25-29 | 24,900 | 36.0 | 797,360 | 37.0 | 121,475 | 21.0 | 78,340 | 30.0 |
| 30-34 | 20,405 | 29.0 | 660,015 | 30.0 | 109,535 | 19.0 | 67,795 | 26.0 |
| 35-39 | 8,610 | 12.0 | 255,870 | 12.0 | 82,310 | 14.0 | 40,550 | 16.0 |
| 40+ | 1,530 | 2.2 | 43,330 | 2.0 | 36,835 | 6.4 | 17,135 | 6.6 |
| **Calendar year of pregnancy** | | | | | | | | |
| 1979-1987 | 13,555 | 20.0 | 379,850 | 17.0 | 141,705 | 25.0 | 52,485 | 20.0 |
| 1988-1994 | 19,660 | 28.0 | 474,450 | 22.0 | 118,945 | 21.0 | 73,380 | 28.0 |
| 1995-2002 | 17,145 | 25.0 | 427,135 | 20.0 | 120,030 | 21.0 | 45,485 | 18.0 |
| 2003-2009 | 11,730 | 17.0 | 471,285 | 22.0 | 114,480 | 20.0 | 52,135 | 20.0 |
| 2010-2017 | 7,140 | 10.0 | 427,220 | 20.0 | 83,195 | 14.0 | 34,940 | 14.0 |
| **Parity at the index date or at the delivery date for pregnancies ending in a childbirth** | | | | | | | | |
| Nulliparous | 0 | 0.0 | 0 | 0.0 | 412,780 | 71.0 | 220,920 | 85.0 |
| Primiparous | 32,790 | 47.0 | 1,028,400 | 47.0 | 45,560 | 7.9 | 15,450 | 6.0 |
| Multiparous | 36,440 | 53.0 | 1,151,540 | 53.0 | 120,015 | 21.0 | 22,060 | 8.5 |
| **Number of pregnancies at the index date** | | | | | | | | |
| 1 | 23,075 | 33.0 | 923,450 | 42.0 | 254,080 | 44.0 | 98,490 | 38.0 |
| 2 | 21,615 | 31.0 | 701,650 | 32.0 | 116,395 | 20.0 | 76,845 | 30.0 |
| 3+ | 24,535 | 35.0 | 554,840 | 25.0 | 207,880 | 36.0 | 83,100 | 32.0 |
| **Civil status** | | | | | | | | |
| Married or in partnership | 40,250 | 58.0 | 1,282,555 | 59.0 | 197,475 | 34.0 | 130,830 | 51.0 |
| Not married | 24,315 | 35.0 | 739,130 | 34.0 | 244,895 | 42.0 | 72,615 | 28.0 |
| missing | 4,660 | 6.7 | 158,255 | 7.3 | 135,980 | 24.0 | 54,985 | 21.0 |
| **Employment status** | | | | | | | | |
| Employed | 48,755 | 70.0 | 1,555,980 | 71.0 | 333,625 | 58.0 | 178,985 | 69.0 |
| Retirement or state pension | 6,285 | 9.1 | 166,125 | 7.6 | 70,190 | 12.0 | 23,880 | 9.2 |
| Unemployed | 10,430 | 15.0 | 325,190 | 15.0 | 125,985 | 22.0 | 37,975 | 15.0 |
| missing | 3,755 | 5.4 | 132,640 | 6.1 | 48,555 | 8.4 | 17,595 | 6.8 |
| **Highest attained education** | | | | | | | | |

| | | | Comparison cohorts | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Characteristic** | **VB-affected childbirths, N = 69,230 (among 65,395 women)** | | **VB-unaffected childbirths, N = 2,179,940 (among 1,172,715 women)** | | **Terminations, N = 578,355 (among 417,765 women)** | | **Miscarriages, N = 258,430 (among 219,680 women)** | |
| | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| Basic education | 21,470 | 31.0 | 535,195 | 25.0 | 248,510 | 43.0 | 75,935 | 29.0 |
| High school or similar | 24,985 | 36.0 | 818,445 | 38.0 | 166,220 | 29.0 | 89,975 | 35.0 |
| Higher education | 16,130 | 23.0 | 605,295 | 28.0 | 73,005 | 13.0 | 62,330 | 24.0 |
| missing | 6,645 | 9.6 | 221,005 | 10.0 | 90,620 | 16.0 | 30,190 | 12.0 |
| **Yearly income, quartiles** | | | | | | | | |
| Q1 | 15,700 | 23.0 | 429,805 | 20.0 | 216,090 | 37.0 | 58,055 | 22.0 |
| Q2 | 16,455 | 24.0 | 509,415 | 23.0 | 127,535 | 22.0 | 59,830 | 23.0 |
| Q3 | 16,225 | 23.0 | 550,835 | 25.0 | 88,275 | 15.0 | 58,855 | 23.0 |
| Q4 | 17,200 | 25.0 | 548,745 | 25.0 | 85,250 | 15.0 | 62,225 | 24.0 |
| missing | 3,645 | 5.3 | 141,140 | 6.5 | 61,205 | 11.0 | 19,465 | 7.5 |
| **Country of origin** | | | | | | | | |
| Denmark | 60,610 | 88.0 | 1,920,450 | 88.0 | 511,065 | 88.0 | 227,980 | 88.0 |
| Other | 8,540 | 12.0 | 256,795 | 12.0 | 67,290 | 12.0 | 30,450 | 12.0 |
| missing | 75 | 0.1 | 2,695 | 0.1 | 0 | 0.0 | 0 | 0.0 |
| **Reproductive history** | | | | | | | | |
| VB diagnosis history | 7,915 | 11.0 | 88,980 | 4.1 | 32,340 | 5.6 | 28,585 | 11.0 |
| VB within 20 gestational weeks history | 3,870 | 5.6 | 40,610 | 1.9 | 16,645 | 2.9 | 8,305 | 3.2 |
| Previous termination of a pregnancy | 15,875 | 23.0 | 341,820 | 16.0 | 166,515 | 29.0 | 52,030 | 20.0 |
| Previous miscarriage | 17,800 | 26.0 | 260,360 | 12.0 | 55,445 | 9.6 | 39,760 | 15.0 |
| **Comorbidities** | | | | | | | | |
| Obesity diagnosis | 1,550 | 2.2 | 120,565 | 5.5 | 13,060 | 2.3 | 6,430 | 2.5 |
| Thyroid disorders | 980 | 1.4 | 34,380 | 1.6 | 6,620 | 1.1 | 3,685 | 1.4 |
| COPD | 660 | 1.0 | 18,295 | 0.8 | 4,885 | 0.8 | 2,165 | 0.8 |
| Chronic kidney disease | 125 | 0.2 | 3,265 | 0.1 | 925 | 0.2 | 410 | 0.2 |
| Chronic liver disease | 95 | 0.1 | 3,380 | 0.2 | 1,015 | 0.2 | 405 | 0.2 |
| Cancer | 285 | 0.4 | 9,225 | 0.4 | 2,415 | 0.4 | 1,120 | 0.4 |
| **Psychiatric comorbidities (1995-2017)** | | | | | | | | |
| Schizophrenia | 360 | 0.5 | 9,185 | 0.4 | 6,035 | 1.0 | 1,490 | 0.6 |
| Autism spectrum disorders | 25 | 0.1 | 815 | 0.1 | 535 | 0.1 | 105 | 0.1 |
| Neurotic | 3,935 | 5.7 | 95,655 | 4.4 | 44,875 | 7.8 | 12,965 | 5.0 |

| | | | Comparison cohorts | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Characteristic** | **VB-affected childbirths, N = 69,230 (among 65,395 women)** | | **VB-unaffected childbirths, N = 2,179,940 (among 1,172,715 women)** | | **Terminations, N = 578,355 (among 417,765 women)** | | **Miscarriages, N = 258,430 (among 219,680 women)** | |
| | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| disorders | | | | | | | | |
| Eating disorders | 480 | 0.7 | 13,650 | 0.6 | 5,755 | 1.0 | 1,640 | 0.6 |
| Personality disorder | 1,435 | 2.1 | 32,825 | 1.5 | 20,275 | 3.5 | 5,195 | 2.0 |
| Alcohol abuse history | 490 | 0.7 | 10,925 | 0.5 | 11,195 | 1.9 | 2,395 | 0.9 |
| History of any psychiatric condition | 5,495 | 7.9 | 145,140 | 6.7 | 64,955 | 11.0 | 19,075 | 7.4 |
| **Comedications (1995-2017)** | | | | | | | | |
| **At least one prescription any time before the index date** | | | | | | | | |
| Antipsychotics | 905 | 1.3 | 26,610 | 1.2 | 13,530 | 2.3 | 4,035 | 1.6 |
| Mood disorders medication | 4,070 | 5.9 | 132,740 | 6.1 | 48,170 | 8.3 | 16,915 | 6.5 |
| Antiepileptics | 710 | 1.0 | 22,550 | 1.0 | 8,050 | 1.4 | 2,935 | 1.1 |
| ADHD | 125 | 0.2 | 4,540 | 0.2 | 3,230 | 0.6 | 605 | 0.2 |
| NSAIDs | 18,015 | 26.0 | 637,605 | 29.0 | 148,140 | 26.0 | 68,610 | 27.0 |
| Aspirin | 120 | 0.2 | 4,290 | 0.2 | 670 | 0.1 | 410 | 0.2 |
| Thyroid disorders | 630 | 0.9 | 23,535 | 1.1 | 4,155 | 0.7 | 2,500 | 1.0 |
| Steroids for systemic use | 2,685 | 3.9 | 98,465 | 4.5 | 19,875 | 3.4 | 10,720 | 4.1 |
| Anti-infectives for systemic use | 31,005 | 45.0 | 1,144,825 | 53.0 | 275,425 | 48.0 | 114,910 | 44.0 |
| **At least one prescription within 30 days before the index date** | | | | | | | | |
| Anti-infectives for systemic use | 2,820 | 4.1 | 78,160 | 3.6 | 32,585 | 5.6 | 9,725 | 3.8 |
| Antiepileptics | 105 | 0.2 | 3,335 | 0.2 | 1,470 | 0.3 | 435 | 0.2 |
| Antidepressants | 250 | 0.4 | 7,070 | 0.3 | 7,005 | 1.2 | 1,610 | 0.6 |
| CVD medications[a] | 180 | 0.3 | 35,515 | 1.6 | 1,675 | 0.3 | 745 | 0.3 |
| NSAIDs | 220 | 0.3 | 1,860 | 0.1 | 5,850 | 1.0 | 1,690 | 0.7 |

[a] CVD medications: clopidogrel, statins, any of antihypertensives

**Table 2. Incidence rates and the number of cardiovascular outcomes following vaginal bleeding-affected childbirths, vaginal bleeding-unaffected pregnancies, pregnancies ending in miscarriages, and pregnancies ending in terminations, Denmark, 1979-2017**

| | VB-affected childbirths | VB-unaffected childbirths | Terminations | Miscarriages |
|---|---|---|---|---|
| **Pregnancies** | | | | |
| | | **N, event** | | |
| **Diabetes type 1** | | | | |
| All | 1,265 | 27,050 | 9,020 | 4,775 |
| First | 315 | 9,570 | 3,950 | 1,820 |
| **Diabetes type 2** | | | | |
| All | 3,870 | 84,230 | 27,810 | 14,365 |
| First | 1,105 | 29,870 | 12,000 | 5,475 |
| **Hypertension** | | | | |
| All | 6,485 | 146,440 | 47,995 | 22,985 |
| First | 1,655 | 48,760 | 21,440 | 8,720 |
| **Ischaemic heart disease** | | | | |
| All | 2,985 | 55,250 | 22,005 | 9,920 |
| First | 680 | 17,180 | 9,215 | 3,600 |
| **Myocardial infarction** | | | | |
| All | 745 | 15,405 | 6,325 | 2,690 |
| First | 170 | 4,790 | 2,760 | 1,010 |
| **Atrial fibrillation or flutter** | | | | |
| All | 1,015 | 21,420 | 8,830 | 3,900 |
| First | 245 | 6,910 | 4,495 | 1,650 |
| **Heart failure** | | | | |
| All | 505 | 10,215 | 4,770 | 2,015 |
| First | 110 | 3,335 | 2,330 | 800 |
| **Ischaemic stroke** | | | | |
| All | 1,295 | 25,465 | 10,590 | 4,430 |
| First | 305 | 8,260 | 4,595 | 1,695 |
| **Hemorrhagic stroke** | | | | |
| All | 565 | 10,900 | 4,255 | 1,805 |
| First | 140 | 3,690 | 1,840 | 660 |
| **CABG** | | | | |
| All | 80 | 1,610 | 815 | 320 |
| First | 20 | 515 | 445 | 150 |
| **PCI** | | | | |
| All | 465 | 10,510 | 4,205 | 1,810 |
| First | 110 | 3,170 | 1,840 | 680 |
| | | **Incidence rate per 10,000 PYs (95% CI)** | | |

| | VB-affected childbirths | VB-unaffected childbirths | Terminations | Miscarriages |
|---|---|---|---|---|
| **Pregnancies** | | | | |
| **Diabetes type 1** | | | | |
| All | 8.28 (7.84-8.75) | 6.37 (6.29-6.44) | 7.32 (7.17-7.47) | 8.65 (8.41-8.90) |
| First | 7.16 (6.41-7.99) | 5.95 (5.83-6.07) | 6.70 (6.49-6.91) | 8.46 (8.08-8.86) |
| **Diabetes type 2** | | | | |
| All | 25.71 (24.91-26.53) | 20.01 (19.88-20.15) | 22.83 (22.56-23.10) | 26.41 (25.98-26.85) |
| First | 25.38 (23.92-26.91) | 18.73 (18.52-18.95) | 20.59 (20.23-20.96) | 25.81 (25.14-26.50) |
| **Hypertension** | | | | |
| All | 43.67 (42.62-44.74) | 35.23 (35.05-35.41) | 39.93 (39.57-40.29) | 42.77 (42.22-43.32) |
| First | 38.36 (36.55-40.24) | 30.89 (30.62-31.16) | 37.30 (36.80-37.80) | 41.60 (40.74-42.49) |
| **Ischaemic heart disease** | | | | |
| All | 19.73 (19.04-20.45) | 13.06 (12.95-13.17) | 18.02 (17.78-18.26) | 18.11 (17.76-18.47) |
| First | 15.47 (14.34-16.66) | 10.71 (10.55-10.87) | 15.77 (15.45-16.09) | 16.84 (16.30-17.40) |
| **Myocardial infarction** | | | | |
| All | 4.85 (4.51-5.21) | 3.61 (3.56-3.67) | 5.12 (4.99-5.25) | 4.86 (4.68-5.04) |
| First | 3.78 (3.24-4.39) | 2.96 (2.88-3.05) | 4.67 (4.50-4.85) | 4.68 (4.40-4.98) |
| **Atrial fibrillation or flutter** | | | | |
| All | 6.64 (6.24-7.06) | 5.03 (4.96-5.09) | 7.15 (7.00-7.30) | 7.04 (6.82-7.27) |
| First | 5.48 (4.82-6.20) | 4.28 (4.18-4.38) | 7.62 (7.40-7.85) | 7.63 (7.27-8.01) |
| **Heart failure** | | | | |
| All | 3.28 (3.01-3.58) | 2.39 (2.35-2.44) | 3.85 (3.74-3.96) | 3.63 (3.47-3.79) |
| First | 2.47 (2.04-2.97) | 2.06 (2.00-2.14) | 3.94 (3.79-4.11) | 3.69 (3.44-3.95) |
| **Ischaemic stroke** | | | | |
| All | 8.47 (8.02-8.94) | 5.98 (5.91-6.06) | 8.59 (8.43-8.76) | 8.01 (7.78-8.25) |
| First | 6.84 (6.10-7.64) | 5.12 (5.01-5.23) | 7.80 (7.58-8.03) | 7.85 (7.48-8.23) |
| **Hemorrhagic stroke** | | | | |
| All | 3.67 (3.38- | 2.56 (2.51- | 3.44 (3.34- | 3.25 (3.11- |

| | VB-affected childbirths | VB-unaffected childbirths | Terminations | Miscarriages |
|---|---|---|---|---|
| **Pregnancies** | | | | |
| | 3.99) | 2.60) | 3.54) | 3.41) |
| First | 3.17 (2.68-3.73) | 2.28 (2.21-2.36) | 3.12 (2.98-3.26) | 3.04 (2.81-3.28) |
| **CABG** | | | | |
| All | 0.53 (0.43-0.66) | 0.38 (0.36-0.40) | 0.66 (0.61-0.70) | 0.58 (0.51-0.64) |
| First | 0.45 (0.28-0.68) | 0.32 (0.29-0.35) | 0.75 (0.69-0.83) | 0.70 (0.59-0.81) |
| **PCI** | | | | |
| All | 3.02 (2.75-3.30) | 2.46 (2.42-2.51) | 3.40 (3.30-3.50) | 3.26 (3.12-3.42) |
| First | 2.49 (2.06-2.99) | 1.96 (1.89-2.03) | 3.11 (2.97-3.26) | 3.14 (2.92-3.39) |

**Table 3. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the associations between vaginal bleeding within 20 weeks of gestation and cardiovascular outcomes, Denmark, 1979-2018**

| Comparisons | Cox regression model | HR (95% CI)[a] |
|---|---|---|
| **Diabetes mellitus type 1** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | **Conventional** | 1.22 (1.15-1.29) |
| VB-affected childbirths vs terminations | | 1.28 (1.20-1.37) |
| VB-affected childbirths vs miscarriages | | 1.00 (0.93-1.07) |
| VB-affected vs VB-unaffected childbirths | **IPTW** | 1.26 (1.19-1.34) |
| VB-affected childbirths vs terminations | | 1.35 (1.25-1.45) |
| VB-affected childbirths vs miscarriages | | 0.99 (0.91-1.08) |
| VB-affected vs VB-unaffected childbirths | **ATT-weighted** | 1.24 (1.17-1.31) |
| VB-affected childbirths vs terminations | | 1.27 (1.19-1.36) |
| VB-affected childbirths vs miscarriages | | 0.92 (0.85-1.00) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | **Conventional** | 1.18 (1.05-1.32) |
| VB-affected childbirths vs terminations | | 1.24 (1.09-1.39) |
| VB-affected childbirths vs miscarriages | | 0.93 (0.82-1.05) |
| VB-affected vs VB-unaffected childbirths | **IPTW** | 1.20 (1.07-1.34) |
| VB-affected childbirths vs terminations | | 1.27 (1.10-1.47) |
| VB-affected childbirths vs miscarriages | | 0.91 (0.80-1.03) |
| VB-affected vs VB-unaffected childbirths | **ATT-weighted** | 1.18 (1.06-1.32) |
| VB-affected childbirths vs terminations | | 1.12 (0.99-1.27) |
| VB-affected childbirths vs miscarriages | | 0.91 (0.80-1.02) |
| **Diabetes mellitus type 2** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | **Conventional** | 1.21 (1.17-1.25) |
| VB-affected childbirths vs terminations | | 1.24 (1.19-1.29) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.97-1.06) |
| VB-affected vs VB-unaffected childbirths | **IPTW** | 1.24 (1.20-1.28) |
| VB-affected childbirths vs terminations | | 1.29 (1.24-1.35) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.97-1.06) |
| VB-affected vs VB-unaffected childbirths | **ATT-weighted** | 1.22 (1.18-1.26) |
| VB-affected childbirths vs terminations | | 1.21 (1.17-1.26) |
| VB-affected childbirths vs miscarriages | | 0.93 (0.89-0.98) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | **Conventional** | 1.34 (1.26-1.42) |

| Comparisons | Cox regression model | HR (95% CI)[a] |
|---|---|---|
| VB-affected childbirths vs terminations | | 1.31 (1.23-1.40) |
| VB-affected childbirths vs miscarriages | | 1.02 (0.96-1.09) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.34 (1.26-1.43) |
| VB-affected childbirths vs terminations | **IPTW** | 1.37 (1.27-1.49) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.94-1.08) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.35 (1.27-1.43) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.23 (1.15-1.32) |
| VB-affected childbirths vs miscarriages | | 1.00 (0.93-1.07) |
| **Hypertension** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.15 (1.12-1.18) |
| VB-affected childbirths vs terminations | **Conventional** | 1.11 (1.08-1.14) |
| VB-affected childbirths vs miscarriages | | 1.02 (0.98-1.05) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.19 (1.16-1.22) |
| VB-affected childbirths vs terminations | **IPTW** | 1.16 (1.12-1.20) |
| VB-affected childbirths vs miscarriages | | 1.02 (0.98-1.06) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.17 (1.14-1.20) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.09 (1.06-1.12) |
| VB-affected childbirths vs miscarriages | | 0.98 (0.94-1.02) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.20 (1.14-1.26) |
| VB-affected childbirths vs terminations | **Conventional** | 1.23 (1.17-1.30) |
| VB-affected childbirths vs miscarriages | | 1.09 (1.03-1.15) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.23 (1.17-1.29) |
| VB-affected childbirths vs terminations | **IPTW** | 1.16 (1.09-1.24) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.96-1.07) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.21 (1.15-1.27) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.10 (1.04-1.16) |
| VB-affected childbirths vs miscarriages | | 1.06 (1.01-1.12) |
| **Ischaemic heart disease** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.31 (1.27-1.36) |
| VB-affected childbirths vs terminations | **Conventional** | 1.11 (1.06-1.16) |
| VB-affected childbirths vs miscarriages | | 1.06 (1.01-1.11) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.42 (1.36-1.47) |
| VB-affected childbirths vs terminations | **IPTW** | 1.17 (1.11-1.23) |
| VB-affected childbirths vs miscarriages | | 1.07 (1.01-1.13) |
| | | |
| VB-affected vs VB-unaffected childbirths | **ATT-weighted** | 1.35 (1.30-1.40) |
| VB-affected childbirths vs terminations | | 1.11 (1.06-1.16) |

| Comparisons | Cox regression model | HR (95% CI)[a] |
|---|---|---|
| VB-affected childbirths vs miscarriages | | 1.02 (0.97-1.08) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.34 (1.25-1.45) |
| VB-affected childbirths vs terminations | **Conventional** | 1.26 (1.16-1.37) |
| VB-affected childbirths vs miscarriages | | 1.17 (1.08-1.27) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.40 (1.30-1.52) |
| VB-affected childbirths vs terminations | **IPTW** | 1.24 (1.13-1.37) |
| VB-affected childbirths vs miscarriages | | 1.09 (1.00-1.19) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.36 (1.26-1.47) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.08 (0.99-1.17) |
| VB-affected childbirths vs miscarriages | | 1.11 (1.02-1.21) |
| **Myocardial infarction** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.17 (1.09-1.26) |
| VB-affected childbirths vs terminations | **Conventional** | 1.00 (0.92-1.09) |
| VB-affected childbirths vs miscarriages | | 0.94 (0.85-1.03) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.26 (1.17-1.36) |
| VB-affected childbirths vs terminations | **IPTW** | 1.02 (0.92-1.12) |
| VB-affected childbirths vs miscarriages | | 0.93 (0.83-1.04) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.20 (1.12-1.29) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.01 (0.93-1.10) |
| VB-affected childbirths vs miscarriages | | 0.93 (0.83-1.04) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.18 (1.02-1.38) |
| VB-affected childbirths vs terminations | **Conventional** | 1.14 (0.97-1.35) |
| VB-affected childbirths vs miscarriages | | 1.04 (0.88-1.23) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.23 (1.06-1.44) |
| VB-affected childbirths vs terminations | **IPTW** | 1.04 (0.86-1.27) |
| VB-affected childbirths vs miscarriages | | 0.95 (0.80-1.14) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.20 (1.03-1.40) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 0.96 (0.82-1.14) |
| VB-affected childbirths vs miscarriages | | 1.00 (0.85-1.19) |
| **Atrial fibrillation or flutter** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.19 (1.12-1.27) |
| VB-affected childbirths vs terminations | **Conventional** | 1.10 (1.02-1.18) |
| VB-affected childbirths vs miscarriages | | 1.00 (0.92-1.09) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.26 (1.19-1.35) |
| VB-affected childbirths vs terminations | **IPTW** | 1.04 (0.96-1.13) |
| VB-affected childbirths vs miscarriages | | 0.98 (0.89-1.08) |

| Comparisons | Cox regression model | HR (95% CI)[a] |
|---|---|---|
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.23 (1.16-1.31) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.05 (0.97-1.12) |
| VB-affected childbirths vs miscarriages | | 0.94 (0.86-1.04) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.15 (1.01-1.31) |
| VB-affected childbirths vs terminations | **Conventional** | 1.05 (0.92-1.21) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.88-1.16) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.25 (1.10-1.42) |
| VB-affected childbirths vs terminations | **IPTW** | 0.84 (0.71-1.00) |
| VB-affected childbirths vs miscarriages | | 0.85 (0.73-0.98) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.19 (1.04-1.35) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 0.89 (0.77-1.02) |
| VB-affected childbirths vs miscarriages | | 0.95 (0.83-1.09) |
| **Heart failure** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.21 (1.11-1.33) |
| VB-affected childbirths vs terminations | **Conventional** | 1.01 (0.92-1.12) |
| VB-affected childbirths vs miscarriages | | 0.96 (0.85-1.08) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.30 (1.19-1.43) |
| VB-affected childbirths vs terminations | **IPTW** | 1.00 (0.89-1.13) |
| VB-affected childbirths vs miscarriages | | 0.94 (0.82-1.08) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.25 (1.14-1.37) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.00 (0.91-1.11) |
| VB-affected childbirths vs miscarriages | | 0.94 (0.82-1.07) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.10 (0.91-1.33) |
| VB-affected childbirths vs terminations | **Conventional** | 1.03 (0.84-1.25) |
| VB-affected childbirths vs miscarriages | | 1.02 (0.83-1.25) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.18 (0.97-1.42) |
| VB-affected childbirths vs terminations | **IPTW** | 0.88 (0.70-1.11) |
| VB-affected childbirths vs miscarriages | | 0.86 (0.70-1.06) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.12 (0.92-1.35) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 0.83 (0.68-1.02) |
| VB-affected childbirths vs miscarriages | | 0.96 (0.78-1.18) |
| **Ischaemic stroke** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.26 (1.19-1.33) |
| VB-affected childbirths vs terminations | **Conventional** | 1.04 (0.98-1.11) |
| VB-affected childbirths vs miscarriages | | 1.02 (0.94-1.09) |

| Comparisons | Cox regression model | HR (95% CI)[a] |
|---|---|---|
| VB-affected vs VB-unaffected childbirths | | 1.33 (1.26-1.41) |
| VB-affected childbirths vs terminations | **IPTW** | 1.05 (0.98-1.13) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.93-1.10) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.29 (1.22-1.36) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.05 (0.99-1.12) |
| VB-affected childbirths vs miscarriages | | 0.98 (0.90-1.07) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.24 (1.10-1.39) |
| VB-affected childbirths vs terminations | **Conventional** | 1.16 (1.03-1.31) |
| VB-affected childbirths vs miscarriages | | 1.08 (0.96-1.23) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.29 (1.15-1.45) |
| VB-affected childbirths vs terminations | **IPTW** | 0.98 (0.84-1.14) |
| VB-affected childbirths vs miscarriages | | 0.96 (0.85-1.10) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.26 (1.12-1.41) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.05 (0.92-1.19) |
| VB-affected childbirths vs miscarriages | | 1.05 (0.93-1.20) |
| **Hemorrhagic stroke** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.27 (1.17-1.39) |
| VB-affected childbirths vs terminations | **Conventional** | 1.10 (1.00-1.21) |
| VB-affected childbirths vs miscarriages | | 1.05 (0.94-1.18) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.37 (1.25-1.49) |
| VB-affected childbirths vs terminations | **IPTW** | 1.05 (0.93-1.17) |
| VB-affected childbirths vs miscarriages | | 1.04 (0.92-1.18) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.30 (1.19-1.41) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.12 (1.02-1.24) |
| VB-affected childbirths vs miscarriages | | 1.05 (0.92-1.19) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.30 (1.10-1.54) |
| VB-affected childbirths vs terminations | **Conventional** | 1.23 (1.03-1.47) |
| VB-affected childbirths vs miscarriages | | 1.19 (0.99-1.43) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.36 (1.15-1.62) |
| VB-affected childbirths vs terminations | **IPTW** | 1.12 (0.90-1.40) |
| VB-affected childbirths vs miscarriages | | 1.11 (0.91-1.35) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.32 (1.11-1.56) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.18 (0.98-1.42) |
| VB-affected childbirths vs miscarriages | | 1.18 (0.98-1.42) |
| **CABG** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | **Conventional** | 1.24 (0.99-1.55) |

| Comparisons | Cox regression model | HR (95% CI)[a] |
|---|---|---|
| VB-affected childbirths vs terminations | | 1.07 (0.84-1.37) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.76-1.36) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.36 (1.08-1.70) |
| VB-affected childbirths vs terminations | **IPTW** | 0.97 (0.72-1.30) |
| VB-affected childbirths vs miscarriages | | 1.00 (0.71-1.41) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.28 (1.02-1.60) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.04 (0.80-1.33) |
| VB-affected childbirths vs miscarriages | | 1.02 (0.73-1.41) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.31 (0.83-2.04) |
| VB-affected childbirths vs terminations | **Conventional** | 1.07 (0.67-1.71) |
| VB-affected childbirths vs miscarriages | | 0.99 (0.61-1.60) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.35 (0.86-2.12) |
| VB-affected childbirths vs terminations | **IPTW** | 0.94 (0.55-1.59) |
| VB-affected childbirths vs miscarriages | | 0.84 (0.51-1.37) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.31 (0.84-2.04) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 0.73 (0.46-1.18) |
| VB-affected childbirths vs miscarriages | | 0.92 (0.57-1.48) |
| **PCI** | | |
| **All pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.05 (0.96-1.16) |
| VB-affected childbirths vs terminations | **Conventional** | 0.96 (0.86-1.06) |
| VB-affected childbirths vs miscarriages | | 0.93 (0.82-1.05) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.14 (1.04-1.25) |
| VB-affected childbirths vs terminations | **IPTW** | 0.99 (0.88-1.12) |
| VB-affected childbirths vs miscarriages | | 0.92 (0.80-1.05) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.09 (0.99-1.19) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 0.97 (0.87-1.07) |
| VB-affected childbirths vs miscarriages | | 0.92 (0.80-1.05) |
| **First pregnancies** | | |
| VB-affected vs VB-unaffected childbirths | | 1.18 (0.98-1.43) |
| VB-affected childbirths vs terminations | **Conventional** | 1.17 (0.96-1.43) |
| VB-affected childbirths vs miscarriages | | 1.05 (0.85-1.29) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.23 (1.02-1.49) |
| VB-affected childbirths vs terminations | **IPTW** | 1.11 (0.88-1.41) |
| VB-affected childbirths vs miscarriages | | 0.98 (0.79-1.22) |
| | | |
| VB-affected vs VB-unaffected childbirths | | 1.20 (0.99-1.45) |
| VB-affected childbirths vs terminations | **ATT-weighted** | 1.01 (0.82-1.24) |
| VB-affected childbirths vs miscarriages | | 1.01 (0.82-1.24) |

CABsG, coronary artery bypass graft; PCI, percutaneous coronary intervention

[a] Adjusted for women's age at pregnancy end, calendar year, parity, civil status, employment, highest attained education, income in year-specific quartiles, reproductive history (previous episodes of vaginal bleeding, terminations, miscarriages), comorbidities (chronic pulmonary disease, chronic kidney disease, chronic liver disease, thyroid, cancer, rheumatic conditions, thyroid conditions, alcohol abuse, and individual classes of psychiatric conditions available starting in 1995); medication use (available starting in 1995) any time before the index (antipsychotics, medication for mood disorders, NSAIDs, aspirin, thyroid disorders medication, steroids for systemic use, anti-infectives for systemic use) and 30 days before the index date (anti-infectives for systemic use, antidepressants, any of clopidogrel, statins, antihypertensives, NSAIDs)


1,490,389 records:
Still- and live-births in Denmark, 1973-1996:
1,483,364 Livebirths
7025 Stillbirths
1,338,638 records:
Still- and live-births in Denmark, 1997-2017:
1,332,848 Livebirths
5790 Stillbirths
2,829,027 records:
Still- and live-births in Denmark, 1973-2017
2,816,212 Live-births
12,815 Stillbirths
Including 89,723 infants born from multi-fetal delivery
N, women = 1,443,429
203,528 records:
Vaginal bleeding hospital diagnoses, the DNPR (1977-2018); N, women = 120,697
414,405 records:
Hospital diagnoses for miscarriages, the DNPR (1977-2018); N, women = 243,743
One identifier randomly selected for each multi-fetal delivery is kept (N=44,458)
2,783,747
2,771,570 Live births
12,177 Stillbirths
92,806 records:
Vaginal bleeding hospital diagnoses within 20 gestational weeks
N, women = 67,555
287,426 records:
Distinct primary and secondary diagnoses at hospital encounters for miscarriages, the DNPR (1977-2018); N, women = 243,743
Excluded
402,068 Records outside of the study period (<1979)
747,237 records:
Hospital diagnoses for pregnancy terminations, the DNPR (1977-2018); N, women = 453,396
241,974 records:
Hospital procedure records for pregnancy terminations, the DNPR (1977-2018); N, women = 183,804
2,381,679 records:
Pregnancies ending in still- and live births, 1979-2017
N, women = 1,240,002
646,224 records:
Distinct records for pregnancy terminations, the DNPR (1977-2018); N, women = 465,813
3,408,135 Eligible pregnancies
N, women = 1,411,869
Excluded 322,182 records:
14,511 Repeated episodes of vaginal bleeding in pregnancy
71,450 Unknown gestational age
6,749 Encounters for different reproductive events (delivery, miscarriage, termination, vaginal bleeding) registered on the same date
67,923 Dates of encounters for reproductive events (delivery, miscarriage, termination, vaginal bleeding) are outside of the study period (< 1979 or > 2017)
68,999 Excluded from unaffected childbirths comparator cohort due to vaginal bleeding episode
78,456 History of any outcome of interest (CVD, hypertension or diabetes types 1 and 2) before the index date
10,911 Personal identifier not found in the CRS or age of < 10 at the date of reproductive event
3,183 Emigrated before the index date
Final study population (clouded)
3,085,955 pregnancies (1979-2017) among 1,329,331 distinct women
2,179,940 Pregnancies unaffected by vaginal bleeding ending in childbirths among 1,172,715 women
69,230 Pregnancies affected by vaginal bleeding within 20 gestational weeks and ending in a childbirth among 65,395 women
578,355 Pregnancies ending in a termination among 417,765 women
258,430 Pregnancies ending in a miscarriage among 219,680 women